Biotech Stock Scores Big Win, Squeezes Shorts

Group 1 - Viridian Therapeutics Inc (NASDAQ:VRDN) stock increased by 11.1% to $15.75, reaching a high of$16.35 after a late-stage study for its eye disorder treatment met its main goal [1] - Despite the recent increase, VRDN shares are still down 28% year to date, and momentum has not reached the 200-day moving average [2] - A short squeeze may support the stock's upward movement, as short interest decreased by 7.3% in the last two reporting periods, with 8 million shares sold short, representing 12.9% of the total float [2] Group 2 - There has been significant put trading activity for Viridian, with 6,000 puts bought to open in the last 10 days compared to only 460 calls [3]